Palonosetron Fresenius Kabi (Palonosetron Hydrochloride)

Palonosetron Hydrochloride, the active ingredient in Palonosetron Fresenius Kabi, is a 5‑HT₃ receptor antagonist presented as a sterile injectable solution for intravenous use. It is employed to prevent chemotherapy‑induced nausea and vomiting in adult cancer patients. GNH USA supplies Palonosetron Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Palonosetron Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Palonosetron Fresenius Kabi is a selective 5‑HT₃ receptor antagonist used in the management of chemotherapy‑related nausea and vomiting.

- Chemotherapy‑induced nausea and vomiting (CINV): helps prevent both acute and delayed episodes in adult patients receiving moderately to highly emetogenic chemotherapy. - Post‑operative nausea and vomiting (PONV): reduces the incidence of nausea and vomiting after surgical procedures requiring general anesthesia. - Radiotherapy‑induced nausea and vomiting: mitigates nausea associated with high‑dose radiation treatments. - Antiemetic prophylaxis in stem‑cell transplantation: provides nausea control during conditioning regimens. - Nausea related to other emetogenic agents: offers relief when other drugs may cause vomiting. - Adjunctive antiemetic therapy: used in combination with other antiemetics for broader coverage.

Palonosetron is generally well‑tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate headache reported in clinical studies. - Constipation: occasional reduced bowel movements. - Fatigue: transient feeling of tiredness. - Dizziness: light‑headed sensations. - Injection site reactions: mild erythema or discomfort at the site of administration.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, pruritus, or anaphylaxis. - Cardiac arrhythmias: QT‑interval prolongation in susceptible individuals. - Severe constipation or intestinal obstruction. - Serotonin syndrome: rare when combined with other serotonergic agents. - Neuroleptic malignant syndrome: extremely rare but reported.

Palonosetron should be administered ​​​  ​  

-   g    ...